Profil
Laura G.
Hansen is currently Vice President-Investor Relations at Denali Therapeutics, Inc. since 2020.
Former positions include Vice President-Corporate Affairs at BlackThorn Therapeutics, Inc. (2019–2020), Vice President-Investor Relations at Aimmune Therapeutics, Inc. (2016–2019), Senior Director-Corporate Communications at Threshold Pharmaceuticals, Inc. (2012–2016), Director-Corporate Communications at Kyntra Bio, Inc. (2002–2012), and Director-Corporate Communications at Corvas International, Inc. (2001–2002).
Education includes undergraduate and doctorate degrees from The University of Texas at Austin.
Aktive Positionen von Laura Hansen
| Unternehmen | Position | Beginn |
|---|---|---|
| DENALI THERAPEUTICS INC. | Investor Relations Kontakt | 01.09.2020 |
Ehemalige bekannte Positionen von Laura Hansen
| Unternehmen | Position | Ende |
|---|---|---|
BlackThorn Therapeutics, Inc.
BlackThorn Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets medicines for neuron developmental disorders | Corporate Officer/Principal | 01.09.2020 |
| AIMMUNE THERAPEUTICS, INC. | Investor Relations Kontakt | 01.03.2019 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biotechnology company | Investor Relations Kontakt | 01.02.2016 |
| KYNTRA BIO, INC. | Public Communications Contact | 01.07.2012 |
Corvas International, Inc.
Corvas International, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic agents for cardiovascular, cancer, and other diseases | Public Communications Contact | 01.07.2002 |
Ausbildung von Laura Hansen
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Corvas International, Inc.
Corvas International, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic agents for cardiovascular, cancer, and other diseases | Health Technology |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biotechnology company | Health Technology |
FibroGen, Inc.
FibroGen, Inc. Pharmaceuticals: MajorHealth Technology Develops biotechnology-based drugs | Health Technology |
The University of Texas at Austin
The University of Texas at Austin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Engages in the development of desensitization treatments for peanut and food allergies | Health Technology |
BlackThorn Therapeutics, Inc.
BlackThorn Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets medicines for neuron developmental disorders | Health Technology |
Denali Therapeutics, Inc.
Denali Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops therapeutics for neurodegenerative diseases | Health Technology |
















